Payment overview · 2025
General Payments
$133.97
6 reported records · 5 companies
Healthcare provider profile · identity verified
James Wyatt Stephens, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MONTICELLO, MS · NPI 1326248774
Verified facts
What the public records show
CMS Open Payments records show James Wyatt Stephens, M.D. received $133.97 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.51 | 28.8% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $28.59 | 21.3% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $27.98 | 20.9% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $21.58 | 16.1% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $17.31 | 12.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $133.97 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 408 | 95 |
| Omeprazole | Omeprazole | 332 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 66 |
| Gabapentin | Gabapentin | 310 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 51 |
| Lisinopril | Lisinopril | 254 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 53 |
| Losartan Potassium | Losartan Potassium | 205 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 37 |
| Ezetimibe | Ezetimibe | 190 | 47 |
| Simvastatin | Simvastatin | 189 | 50 |
| Furosemide | Furosemide | 181 | 48 |
| Trazodone Hcl | Trazodone Hcl | 177 | 30 |
| Famotidine | Famotidine | 175 | 41 |
| Valsartan | Valsartan | 173 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 156 | 35 |
| Verapamil Er | Verapamil Hcl | 152 | 30 |
| Fluconazole | Fluconazole | 151 | 94 |
| Potassium Chloride | Potassium Chloride | 146 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 137 | 32 |
| Azithromycin | Azithromycin | 127 | 94 |
| Meloxicam | Meloxicam | 123 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 27 |
| Celecoxib | Celecoxib | 119 | 29 |
| Carvedilol | Carvedilol | 110 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 43 |
| Pregabalin | Pregabalin | 107 | 20 |
| Metformin Hcl Er | Metformin Hcl | 105 | 26 |
| Montelukast Sodium | Montelukast Sodium | 105 | 22 |
| Buspirone Hcl | Buspirone Hcl | 98 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 17 |
| Lovastatin | Lovastatin | 90 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 18 |
| Sertraline Hcl | Sertraline Hcl | 82 | 21 |
| Baclofen | Baclofen | 79 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 62 |
| Glimepiride | Glimepiride | 72 | 15 |
| Allopurinol | Allopurinol | 70 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 21 |
| Eliquis | Apixaban | 69 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 17 |
| Bupropion Xl | Bupropion Hcl | 68 | suppressed |
| Aripiprazole | Aripiprazole | 67 | 11 |
| Metformin Hcl | Metformin Hcl | 65 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Xarelto | Rivaroxaban | 61 | 11 |
| Jardiance | Empagliflozin | 60 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 11 |
| Methylprednisolone | Methylprednisolone | 58 | 50 |
| Fenofibrate | Fenofibrate | 57 | 15 |
| Nifedipine Er | Nifedipine | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 17 |
| Meclizine Hcl | Meclizine Hcl | 47 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 34 |
| Mupirocin | Mupirocin | 46 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Irbesartan | Irbesartan | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Verapamil Sr | Verapamil Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Prednisone | Prednisone | 20 | 14 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Minoxidil | Minoxidil | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $133.97 · 6 records | ABBVIE INC. | AURYON LASER SYSTEM 100-120 VAC, COLLAGENASE SANTYL, DALVANCE, Miro3D, RotarexS 6 F x 135 cm | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error